PLMA_1170x120_10-8-21

Dr. Reddy’s

Dr. Reddy’s Kalawadia on the generic drug industry

Dr. Reddy’s Kalawadia on the generic drug industry

Milan Kalawadia, who has oversight for product management/marketing for U.S. generics for Dr. Reddy’s Laboratories, has been with the company for over a decade and a half. In this interview he details his responsibilities for Dr. Reddy’s extensive U.S. operations, as well as exploring the challenges of the pandemic. He also discusses the company’s relationship

Dr. Reddy’s Laboratories introduces Icosapent Ethyl Capsules

Dr. Reddy’s Laboratories introduces Icosapent Ethyl Capsules

PRINCETON, N.J. — Dr. Reddy’s Laboratories recently announced the launch of Icosapent Ethyl Capsules, 1 gram approved by the U.S. Food and Drug Administration. Dr. Reddy’s Icosapent Ethyl Capsules, 1 gram is approved for the following indication: as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥ 500 mg/dL)

Dr. Reddy’s announces the launch of Ertapenem for Injection in the U.S. market

Dr. Reddy’s announces the launch of Ertapenem for Injection in the U.S. market

HYDERBAD, India and PRINCETON, N.J. —  Dr. Reddy’s Laboratoriesannounced the launch of Ertapenem for Injection, 1 g/vial, a therapeutic equivalent generic version of INVANZ (ertapenem for injection) for injection, 1 g/vial approved by the U.S. Food and Drug Administration (USFDA). “We are pleased to bring this important product to market at this time,” says Marc

Dr. Reddy’s undaunted by supply chain challenges

Dr. Reddy’s undaunted by supply chain challenges

NEW YORK — Dr. Reddy’s has approached the COVID-19 pandemic with its customary patient-centric philosophy to continue supplying products as quickly as possible. Vincent Colicchio, vice president of supply chain and external manufacturing for Dr. Reddy’s Laboratories North America, says the challenge was to maintain production from the company’s manufacturing sites in its home country

Dr. Reddy’s launches febuxostat tablets

Dr. Reddy’s launches febuxostat tablets

PRINCETON, N.J. — Dr. Reddy’s Laboratories  announced the launch of febuxostat tablets, a therapeutic equivalent generic version of Uloric (febuxostat) tablets approved by the U.S. Food and Drug Administration (USFDA). The Uloric brand and generic had U.S. sales of approximately $108 million MAT for the most recent twelve months ending in October 2020 according to

Dr. Reddy’s files application for COVID treatment in Canada

Dr. Reddy’s files application for COVID treatment in Canada

MISSISSAUGA, Ontario — Dr. Reddy’s has filed an application  for Reeqonus (favipiravir) tablets for acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. Reeqonus is also known as Avigan, which was developed by Fujifilm Toyama Chemical

Dr. Reddy’s goes paperless in validation with ValGenesis VLMS

Dr. Reddy’s goes paperless in validation with ValGenesis VLMS

SAN FRANCISCO — ValGenesis, a market leader in Enterprise Validation Lifecycle Management Solutions (VLMS), announced on Monday that it has digitized the validation process at Dr. Reddy’s Laboratories across multiple sites, driven by ValGenesis VLMS – the industry’s most trusted electronic validation lifecycle management system. Dr. Reddy’s Laboratories is a global integrated pharmaceutical company operating

Dr. Reddy’s introduces ziprasidone mesylate for injection

Dr. Reddy’s introduces ziprasidone mesylate for injection

PRINCETON, N.J. — Dr. Reddy’s  has launched ziprasidone mesylate for injection, 20 mg (base)/mL single-dose vials, the therapeutic generic equivalent of Geodon (ziprasidone mesylate) Injection, 20 mg/mL, approved by the U.S. Food and Drug Administration. “We’re pleased to bring the first generic of ziprasidone mesylate for injection to market for patients who will benefit from

Dr. Reddy’s launches trientine hydrochloride capsules

Dr. Reddy’s launches trientine hydrochloride capsules

PRINCETON, N.J. — Dr. Reddy’s announced the launch of trientine hydrochloride capsules USP, 250 mg, a therapeutically equivalent generic version of Syprine (trientine hydrochloride) Capsules, approved by the U.S. Food and Drug Administration. “We are pleased to provide this convenient alternative for patients, pharmacists and distribution partners,” explains Marc Kikuchi, chief executive officer and head

Dr. Reddy’s launches O-T-C, store-brand equivalent of Prevacid 24HR capsules

Dr. Reddy’s launches O-T-C, store-brand equivalent of Prevacid 24HR capsules

PRINCETON, N.J. — Dr. Reddy’s announced Monday the launch of lansoprazole delayed-release capsules USP, 15 mg, an over-the-counter (O-T-C) store-brand equivalent of Prevacid 24HR capsules, in the United States market, as approved by the U.S. Food and Drug Administration. Dr. Reddy’s O-T-C lansoprazole delayed-release capsules USP, 15 mg, is an over-the-counter, Proton Pump Inhibitor (PPI)

Amneal among companies to launch generic version of Lyrica

Amneal among companies to launch generic version of Lyrica

BRIDGEWATER, N.J.  — The Food and Drug Administration has approved a number of applications for the generic version of Pfizer’s Lyrica (pregabalin). The  FDA gave the green light to the following companies: Amneal, Alembic, Alkem, Dr. Reddy’s, InvaGen, MSN Laboratories, Rising Pharmaceuticals, Sciegen, and Teva. Amneal’s  generic version of Lyrica (pregabalin capsules) will be available

Dr. Reddy’s intros generic O-T-C version of Allegra-D

Dr. Reddy’s intros generic O-T-C version of Allegra-D

PRINCETON, N.J. — Dr. Reddy’s Laboratories has introduced an over-the-counter store-brand equivalent of Chattem’s Allegra-D (fexofenadine 60 mg and pseudoephedrine 120 mg) extended-release tablets. This is an O-T-C store-brand equivalent of Allegra-D 12 HR Allergy and Congestion Extended-Release Tablets, in the United States market, as approved by the U.S. Food and Drug Administration (USFDA).  “We

Dr. Reddy’s releases O-T-C store brand equivalent of Mucinex D extended release tablets

Dr. Reddy’s releases O-T-C store brand equivalent of Mucinex D extended release tablets

PRINCETON, N.J. — Dr. Reddy’s announced launch of an over-the-counter (O-T-C) store-brand equivalent of Mucinex D Extended Release Tablets in two strengths— guaifenesin 600 mg and pseudoephedrine HCl 60 mg, and guaifenesin 1200 mg and pseudoephedrine HCl 120 mg—in the United States market, as approved by the U.S. Food and Drug Administration (USFDA). Dr. Reddy’s